News and Press Releases
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International,...
Category: Clinical Trials, Drug Discovery
Posted: May 5, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development...
Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024
Johnson & Johnson receives positive CHMP opinion for RYBREVANT▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is...
Category: Clinical Trials, Pharmaceutical
Posted: April 29, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Osteolabs to Present New Clinical Data from Over 2,400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress
New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control 9 April 2024 -- Kiel, Germany -- Osteolabs,...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: April 12, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US
9 April 2024 -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...
Category: Clinical Trials
Posted: April 9, 2024
G.ST Antivirals reports start of Phase 2 trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer
Phase 2 clinical trial started, first subject in on 2 April 2024 New CMO Ronald Bruce Turner MD, distinguished expert in the clinical research of rhinoviruses, to oversee trial and...
Category: Biotechnology, Clinical Trials
Posted: April 9, 2024
University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study
The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...
Category: Biotechnology, Clinical Trials
Posted: April 3, 2024
Headlands Research Announces Fifth Research Site under Partnership with Pfizer to Improve Diversity in Clinical Trials
Headlands Research Orlando satisfies the organisations’ commitment to create multiple research sites aimed at increasing health equity in clinical research 28 March 2024 -- California, US -- Headlands Research, a...
Category: Clinical Trials
Posted: April 2, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Phastar’s Clinical Intelligence Portal Shortlisted as Finalist in 2024 Citeline Award
High quality data visualisation and advanced recruitment forecasting app shapes success story in Best Sponsor Facing Initiative 25 March 2024 -- London, UK, and North Carolina, US -- Phastar, a...
Category: Clinical Trials
Posted: March 25, 2024
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial
Treatment for rare childhood disease was well tolerated and slowed loss of motor function 20 March 2024 -- Maryland, US -- An investigational gene therapy for a rare neurodegenerative disease...
Category: Clinical Trials, Drug Discovery
Posted: March 20, 2024
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming phase 2b study following successful phase 1b/2a study 12 March 2024 -- Cambridgeshire and Belfast, UK --...
Category: Clinical Trials
Posted: March 12, 2024
